Published in Healthcare Finance, Tax and Law Weekly, December 17th, 2008
The MS Society supports the advice from the ISSCR that patients and their families should approach stem cell therapy with caution.
The Society has this week warned people with MS of a 'stem cell trial' being marketed from the Seychelles and Dubai, due to a lack of current evidence to support a stem cell treatment for MS.
It is understood that a company called Integrated BioSciences (IBS), registered in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.